Edesa Biotech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
EDSA Nasdaq 8731 https://www.edesabiotech.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Edesa Biotech Inc

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference - Mar 23rd, 2023 8:30 pm
Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting - Mar 16th, 2023 8:10 pm
Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study - Mar 15th, 2023 12:10 pm
EDSA: Positive News Flow to Start 2023… - Feb 15th, 2023 10:11 am
Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Invest In Growth? - Feb 12th, 2023 2:00 pm
Edesa Biotech Reports Fiscal 1st Quarter 2023 Results - Feb 10th, 2023 2:00 pm
Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study - Feb 1st, 2023 1:15 pm
EDSA: 1.0% EB01 Cream Achieves Primary Endpoint in Phase 2b Trial… - Jan 18th, 2023 10:50 am
Edesa Biotech's Dermatitis Study Data Fails To Cheer Investors - Jan 17th, 2023 5:30 pm
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug - Jan 17th, 2023 1:30 pm
EDSA: Phase 2b Data for EB01 Anticipated in January 2023… - Dec 22nd, 2022 11:47 am
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate - Dec 20th, 2022 1:30 pm
Edesa Biotech Reports Fiscal Year 2022 Results - Dec 16th, 2022 2:00 pm
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference - Dec 2nd, 2022 1:00 pm
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market - Nov 3rd, 2022 1:00 pm
EDSA: Statistically Significant Mortality Reduction in Phase 2 ARDS Trial… - Oct 3rd, 2022 3:10 pm
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study - Sep 30th, 2022 12:00 pm
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference - Sep 8th, 2022 8:30 pm
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment - Sep 7th, 2022 12:00 pm
EDSA: Phase 3 ARDS Study Expanded to Include Mechanically Ventilated Patients… - Aug 24th, 2022 11:15 am